Derivado de piperazina

• Main Authors: SUGASAWA, Keizo, MAENO, Kyoichi, MIHARA, Hisashi, MAKINO, Takuya, OSODA, Kazuhiko, MORITOMO, Hiroyuki, HOSOGAI, Naomi, ASAI, Norio, YONETOKU, Yasuhiro, SHIMIZU, Takafumi, SUGANE, Takashi, YAMASHITA, Daisuke, TANABE, Daisuke
• Format: Patent
• Language: Spanish
• Published: 12.06.2018
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Problema Proporcionar un compuesto que pueda usarse como agonista del receptor MC4. Medio para solucionarlo Los presentes inventores han investigado agonistas del receptor MC4, y han encontrado que un derivado de piperazina tiene acción relacionada con los agonistas, con lo cual se completa la presente invención. Es decir que el derivado de piperazina de la presente invención tiene acción agonista del receptor MC4, y se puede usar como agente para prevenir y/o tratar enfermedades de la vejiga y/o el tracto urinario, en particular, vejiga hipoactiva, vejiga hipotónica, vejiga acontráctil, hipoactividad del detrusor, vejiga neurogénica, falla de la relajación uretral, disinergia detrusor-esfínter uretral externo e hiperplasia prostática benigna. [Problem] To provide a compound which can be used as an MC 4 receptor agonist. [Means for Solution] The present inventors have investigated MC 4 receptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MC 4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.